Tirzepatide is a synthetic dual agonist with activity at both the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR). It is the reference dual-incretin construct in the current literature.
Structurally it is a 39-amino-acid peptide built on a GIP backbone with substitutions that confer GLP-1R activity, plus a C20 fatty-diacid side chain for albumin binding and half-life extension. Its two non-standard residues resist enzymatic cleavage, which is what allows a single molecule to act at two receptors over a long exposure window in research models.
Vantage lists this compound under the catalog name VA-2T. The catalog
name and the vial label use the short form; the compound is tirzepatide, and this page is the
reference record for it.
A note on the catalog name. The Vantage short form is VA-2T, where the numeral denotes the second entry in the incretin line rather than a receptor. Tirzepatide is a GLP-1 and GIP receptor dual agonist; it is not an agonist at the GLP-2 receptor, which is a separate and unrelated target.
Verified dataVerified compound data
| Property | Value |
|---|---|
| Compound name | Tirzepatide |
| Catalog name | VA-2T |
| CAS number | 2023788-19-2 |
| PubChem CID | 166567236 |
| Molecular formula | C225H348N48O68 |
| Molecular weight | ~4813 g/mol |
| Length | 39 residues |
| Physical form | Lyophilized powder, or pre-formulated solution in a sealed research pen |
Molecular formula, molecular weight and registry data verified against PubChem
(CID 166567236).
Research-context mechanism
Preclinical work on tirzepatide centres on co-activation of two class B GPCRs from a single ligand, and on what that co-activation produces relative to GLP-1R agonism alone in the same experimental system. Reported signaling is imbalanced rather than symmetric: the molecule behaves as a full agonist at GIPR and a comparatively weaker partial agonist at GLP-1R, with a distinctive cAMP and beta-arrestin recruitment profile that is itself an active area of receptor-pharmacology study.
These mechanisms are described strictly as they appear in in vitro and animal research
models. They are not established human-use mechanisms, and nothing on this page describes an
approved therapeutic use, an outcome, or a protocol.
Current research summary
- Dual GLP-1R and GIPR co-activation from a single ligand
- Biased agonism, beta-arrestin recruitment and receptor internalisation
- Pancreatic islet and beta-cell secretory models
- GIP receptor biology and its crosstalk with the GLP-1 pathway
- Adipocyte and hepatocyte models under dual-incretin receptor activation
- Comparative incretin pharmacology against mono- and triple-agonist constructs
How identity and purity are verified
Every lyophilized lot Vantage publishes carries a batch Certificate of Analysis on its own
product page, showing the HPLC purity result and the mass-spectrometry identity result for
that specific lot. The certificate is issued by the manufacturer’s contract laboratory.
Vantage describes it as a batch COA and makes no claim of buyer-contracted independent
testing.
Purity publishes at the site specification of 98% or greater by HPLC. Mass-spectrometry
identity is reported against the compound’s own theoretical mass, which for tirzepatide is
approximately 4813 g/mol as listed in the table above. Where a lot has no certificate on
file, no certificate is shown and no testing claim is made for it.
The certificate for the current lot is published on the product page:
VA-2T, 5mg lyophilized vial. The pre-formulated research pen is a
separate listing at VA-2T Pen; pens are supplied as a
sealed pre-formulated solution and do not carry a lot certificate.
Frequently Asked Questions
What is tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist at the GLP-1 and GIP receptors from a single molecule. It is studied in preclinical receptor-pharmacology and islet research models, is supplied as a lyophilized powder, and is not approved for human use.
What is the molecular formula of tirzepatide?
The molecular formula of tirzepatide is C225H348N48O68, with a molecular weight of approximately 4813 g/mol (PubChem CID 166567236).
What is the CAS number for tirzepatide?
The CAS registry number for tirzepatide is 2023788-19-2.
Is VA-2T the same compound as tirzepatide?
Yes. VA-2T is the Vantage catalog name for tirzepatide. The catalog name and the vial label use the short form; the compound supplied is tirzepatide, and its identity is confirmed on the batch Certificate of Analysis for each lot.
Is tirzepatide approved for human use?
No. Tirzepatide is not supplied as an approved drug and is not intended for human consumption. It is offered strictly as a research compound for laboratory use.
Does each tirzepatide lot come with a COA?
Yes. Every lyophilized lot carries a batch Certificate of Analysis published on its product page, reporting HPLC purity and mass-spectrometry identity for that specific lot against the theoretical mass of approximately 4813 g/mol.
Related references
Vantage documents the other incretin-pathway compounds in its catalog at
semaglutide, tirzepatide and
retatrutide. All are listed under
incretin receptor agonists.
For research use only. Not for human or veterinary use. Not approved by the FDA. 21+
- HPLC + MS tested, on tested lots
- U.S. synthesized
- Batch COA on the pages that carry one